OGFOD1

Summary

OGFOD1 (2-oxoglutarate and iron dependent oxygenase domain containing 1, HGNC:25585) is a protein-coding gene on chromosome 16q13, encoding Prolyl 3-hydroxylase OGFOD1 (Q8N543). Prolyl 3-hydroxylase that catalyzes 3-hydroxylation of ‘Pro-62’ of small ribosomal subunit uS12 (RPS23), thereby regulating protein translation termination efficiency.

Enables peptidyl-proline 3-dioxygenase activity. Involved in several processes, including peptidyl-proline hydroxylation; regulation of translational termination; and stress granule assembly. Located in cytoplasmic stress granule; cytosol; and nucleoplasm.

Source: NCBI Gene 55239 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 48 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_018233

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25585
Approved symbol	OGFOD1
Name	2-oxoglutarate and iron dependent oxygenase domain containing 1
Location	16q13
Locus type	gene with protein product
Status	Approved
Aliases	KIAA1612, FLJ10826, TPA1
Ensembl gene	ENSG00000087263
Ensembl biotype	protein_coding
OMIM	615857
Entrez	55239

Gene structure

Transcript identifiers

Ensembl transcripts: 16 — 9 protein_coding, 3 nonsense_mediated_decay, 2 retained_intron, 2 protein_coding_CDS_not_defined

ENST00000336111, ENST00000561646, ENST00000562150, ENST00000563733, ENST00000565209, ENST00000565682, ENST00000566157, ENST00000568172, ENST00000568397, ENST00000569645, ENST00000569802, ENST00000877349, ENST00000877350, ENST00000924152, ENST00000924153, ENST00000966422

RefSeq mRNA: 8 — MANE Select: NM_018233 NM_001324357, NM_001324358, NM_001324359, NM_001324360, NM_001324361, NM_001324362, NM_001324363, NM_018233

CCDS: CCDS10761

Canonical transcript exons

ENST00000566157 — 13 exons

Exon	Start	End
ENSE00001436367	56451554	56451766
ENSE00002602938	56476044	56479104
ENSE00003474703	56470487	56470791
ENSE00003522927	56466152	56466268
ENSE00003576445	56474828	56474950
ENSE00003591445	56453263	56453408
ENSE00003600641	56467165	56467293
ENSE00003603482	56470003	56470082
ENSE00003622354	56458548	56458594
ENSE00003660747	56475507	56475565
ENSE00003675789	56467905	56468018
ENSE00003685748	56466876	56466967
ENSE00003685906	56462534	56462634

Expression profiles

Bgee: expression breadth ubiquitous, 277 present calls, max score 96.29.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 25.0623 / max 199.4382, expressed in 1814 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
154222	24.2057	1814
154223	0.8566	603

Top tissues by expression

285 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
adrenal tissue	UBERON:0018303	96.29	gold quality
oocyte	CL:0000023	96.06	gold quality
gastrocnemius	UBERON:0001388	95.54	gold quality
muscle of leg	UBERON:0001383	95.39	gold quality
muscle organ	UBERON:0001630	94.41	gold quality
secondary oocyte	CL:0000655	94.30	gold quality
biceps brachii	UBERON:0001507	93.75	gold quality
hindlimb stylopod muscle	UBERON:0004252	93.71	gold quality
tibialis anterior	UBERON:0001385	93.60	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	93.49	gold quality
deltoid	UBERON:0001476	93.02	gold quality
skeletal muscle tissue	UBERON:0001134	92.31	gold quality
gingival epithelium	UBERON:0001949	92.14	gold quality
vastus lateralis	UBERON:0001379	92.00	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	91.97	gold quality
stromal cell of endometrium	CL:0002255	91.91	gold quality
quadriceps femoris	UBERON:0001377	91.85	gold quality
adrenal gland	UBERON:0002369	91.46	gold quality
right adrenal gland cortex	UBERON:0035827	91.30	gold quality
islet of Langerhans	UBERON:0000006	91.18	gold quality
right adrenal gland	UBERON:0001233	91.09	gold quality
calcaneal tendon	UBERON:0003701	91.09	gold quality
left adrenal gland	UBERON:0001234	91.08	gold quality
endometrium	UBERON:0001295	90.86	gold quality
left adrenal gland cortex	UBERON:0035825	90.84	gold quality
adrenal cortex	UBERON:0001235	90.76	gold quality
muscle tissue	UBERON:0002385	90.58	gold quality
gingiva	UBERON:0001828	90.57	gold quality
popliteal artery	UBERON:0002250	90.32	gold quality
tibial artery	UBERON:0007610	90.30	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

45 targeting OGFOD1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-539-5P	99.93	70.30	2855
HSA-MIR-95-5P	99.89	72.17	3973
HSA-MIR-4420	99.82	70.08	1624
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-181B-2-3P	99.81	70.06	1646
HSA-MIR-181B-3P	99.81	70.06	1646
HSA-MIR-4659A-3P	99.80	72.62	4248
HSA-MIR-4659B-3P	99.80	72.62	4248
HSA-MIR-448	99.79	72.37	2103
HSA-MIR-8076	99.78	68.52	1170
HSA-MIR-92A-2-5P	99.75	67.01	2164
HSA-MIR-4524A-3P	99.72	66.85	2406
HSA-MIR-3689A-3P	99.70	65.73	2306
HSA-MIR-3689B-3P	99.70	65.71	2311
HSA-MIR-3689C	99.70	65.71	2311
HSA-MIR-5004-5P	99.68	66.63	1294
HSA-MIR-7161-5P	99.68	68.92	1592
HSA-MIR-548U	99.65	67.78	1463
HSA-MIR-6757-3P	99.63	66.88	1089
HSA-MIR-4328	99.57	71.06	4094
HSA-MIR-516B-5P	99.56	66.33	1495
HSA-MIR-7106-5P	99.53	67.47	3574
HSA-MIR-4677-3P	99.49	67.91	1246
HSA-MIR-1224-5P	99.48	65.59	803
HSA-MIR-889-5P	99.41	68.75	1025
HSA-MIR-4786-3P	99.36	68.35	1390
HSA-MIR-4263	99.18	69.25	2236

Literature-anchored findings (GeneRIF, showing 7)

• Data suggest that OGFOD1 plays important proapoptotic roles in the regulation of translation and HRI-mediated phosphorylation of eIF2alpha in cells subjected to arsenite-induced stress. (PMID:20154146)
• OGFOD1 plays an important role in ischemic cell survival and an OGFOD1 iron binding residue is required for ATPAF1 gene expression. (PMID:20579638)
• OGFOD1 catalyzes prolyl hydroxylation of RPS23 and is involved in translation control and stress granule formation. (PMID:24550447)
• Propose that OGFOD1 is required for breast cancer cell proliferation and is associated with poor prognosis in breast cancer. (PMID:25909288)
• The ribosomal prolyl-hydroxylase OGFOD1 decreases during cardiac differentiation and modulates translation and splicing. (PMID:31112528)
• High OGFOD1 expression is associated with papillomavirus-infected laryngeal papillomas. (PMID:32002629)
• OGFOD1 modulates the transcriptional and proteomic landscapes to alter isoproterenol-induced hypertrophy susceptibility. (PMID:37084634)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	ogfod1	ENSDARG00000036061
mus_musculus	Ogfod1	ENSMUSG00000033009
rattus_norvegicus	Ogfod1	ENSRNOG00000019288
drosophila_melanogaster	sud1	FBGN0265189
caenorhabditis_elegans		WBGENE00015915

Protein

Protein identifiers

Prolyl 3-hydroxylase OGFOD1 — Q8N543 (reviewed: Q8N543)

Alternative names: 2-oxoglutarate and iron-dependent oxygenase domain-containing protein 1, Termination and polyadenylation 1 homolog, uS12 prolyl 3-hydroxylase

All UniProt accessions (7): Q8N543, A0A0A0MTR2, H3BP48, H3BR02, H3BR79, H3BUA6, J3KNR5

UniProt curated annotations — full annotation on UniProt →

Function. Prolyl 3-hydroxylase that catalyzes 3-hydroxylation of ‘Pro-62’ of small ribosomal subunit uS12 (RPS23), thereby regulating protein translation termination efficiency. Involved in stress granule formation.

Subunit / interactions. Monomer.

Subcellular location. Cytoplasm. Nucleus Cytoplasm.

Cofactor. Binds 1 Fe(2+) ion per subunit.

Similarity. Belongs to the TPA1 family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q8N543-1	1	yes
Q8N543-2	2

RefSeq proteins (8): NP_001311286, NP_001311287, NP_001311288, NP_001311289, NP_001311290, NP_001311291, NP_001311292, NP_060703* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR005123	Oxoglu/Fe-dep_dioxygenase_dom	Domain
IPR006620	Pro_4_hyd_alph	Domain
IPR019601	Oxoglutarate/Fe-dep_Oase_C	Domain
IPR039558	TPA1/OFD1_N	Domain
IPR051842	uS12_prolyl_hydroxylase	Family

Pfam: PF10637, PF13661

Catalyzed reactions (Rhea), 1 shown:

• [ribosomal protein uS12]-L-proline + 2-oxoglutarate + O2 = [ribosomal protein uS12]-(3S)-3-hydroxy-L-proline + succinate + CO2 (RHEA:54156)

UniProt features (56 total): strand 22, helix 16, binding site 5, sequence conflict 3, mutagenesis site 2, chain 1, domain 1, splice variant 1, sequence variant 1, region of interest 1, short sequence motif 1, compositionally biased region 1, turn 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
4NHX	X-RAY DIFFRACTION	2.1
4NHY	X-RAY DIFFRACTION	2.6

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8N543-F1	87.41	0.77

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (5): 155; 157; 169; 218; 230

Mutagenesis-validated functional residues (2):

Position	Phenotype
155	loss of function.
157	loss of function.

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-9629569	Protein hydroxylation

MSigDB gene sets: 142 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_TUMORAL_MACROPHAGE_DN, RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_UP, GOMF_OXIDOREDUCTASE_ACTIVITY_ACTING_ON_PAIRED_DONORS_WITH_INCORPORATION_OR_REDUCTION_OF_MOLECULAR_OXYGEN, RORA1_01, GOBP_TRANSLATIONAL_TERMINATION, GOBP_TRANSLATION, WEI_MYCN_TARGETS_WITH_E_BOX, GOBP_POST_TRANSCRIPTIONAL_REGULATION_OF_GENE_EXPRESSION, MCCABE_HOXC6_TARGETS_CANCER_DN, GOBP_ORGANELLE_ASSEMBLY, GOBP_PEPTIDYL_PROLINE_MODIFICATION, GCM_NF2, GOBP_REGULATION_OF_PROTEIN_CONTAINING_COMPLEX_DISASSEMBLY, GOBP_PROTEIN_HYDROXYLATION

GO Biological Process (5): regulation of translational termination (GO:0006449), cell population proliferation (GO:0008283), protein hydroxylation (GO:0018126), peptidyl-proline hydroxylation (GO:0019511), stress granule assembly (GO:0034063)

GO Molecular Function (10): iron ion binding (GO:0005506), L-ascorbic acid binding (GO:0031418), peptidyl-proline dioxygenase activity (GO:0031543), peptidyl-proline 3-dioxygenase activity (GO:0031544), protein binding (GO:0005515), oxidoreductase activity (GO:0016491), oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen (GO:0016705), 2-oxoglutarate-dependent dioxygenase activity (GO:0016706), metal ion binding (GO:0046872), dioxygenase activity (GO:0051213)

GO Cellular Component (5): nucleoplasm (GO:0005654), cytoplasm (GO:0005737), cytosol (GO:0005829), cytoplasmic stress granule (GO:0010494), nucleus (GO:0005634)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
oxidoreductase activity	2
translational termination	1
regulation of translation	1
regulation of protein-containing complex disassembly	1
cellular process	1
protein modification process	1
protein hydroxylation	1
peptidyl-proline modification	1
membraneless organelle assembly	1
transition metal ion binding	1
vitamin binding	1
carboxylic acid binding	1
monosaccharide binding	1
heterocyclic compound binding	1
2-oxoglutarate-dependent dioxygenase activity	1
catalytic activity, acting on a protein	1
peptidyl-proline dioxygenase activity	1
binding	1
catalytic activity	1
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen	1
dioxygenase activity	1
cation binding	1
nuclear lumen	1
intracellular anatomical structure	1
cytoplasm	1
cytoplasmic ribonucleoprotein granule	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

1762 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
OGFOD1	PABPC1	P11940	736
OGFOD1	RPS23	P39028	720
OGFOD1	CAPRIN1	Q14444	698
OGFOD1	JMJD4	Q9H9V9	679
OGFOD1	PABIR1	Q96E09	607
OGFOD1	RIOX2	Q8IUF8	604
OGFOD1	G3BP1	Q13283	587
OGFOD1	RIOX1	Q9H6W3	582
OGFOD1	OGFOD2	Q6N063	558
OGFOD1	TRMT1	Q9NXH9	539
OGFOD1	TYW5	A2RUC4	518
OGFOD1	PLAT	P00750	506
OGFOD1	A0A0B4J2E5	A0A0B4J2E5	505
OGFOD1	YBX1	P16990	474
OGFOD1	RPL27A	P46776	470
OGFOD1	HERPUD2	Q9BSE4	470

IntAct

19 interactions, top by confidence:

A	B	Type	Score
OGFOD1		psi-mi:“MI:0915”(physical association)	0.560
OGFOD1	RPS23	psi-mi:“MI:0915”(physical association)	0.560
	OGFOD1	psi-mi:“MI:0915”(physical association)	0.560
OGFOD1	FEM1A	psi-mi:“MI:0915”(physical association)	0.560
RPS23	OGFOD1	psi-mi:“MI:0915”(physical association)	0.560
SPATA46	MDM4	psi-mi:“MI:0914”(association)	0.530
FGL1	DNM1L	psi-mi:“MI:0914”(association)	0.350
FNTA	YKT6	psi-mi:“MI:0914”(association)	0.350
MRPL42	UBA6	psi-mi:“MI:0914”(association)	0.350
TPRN	PPP1R2	psi-mi:“MI:0914”(association)	0.350
BUD13	RPSA2	psi-mi:“MI:2364”(proximity)	0.270
SF3B4	MED19	psi-mi:“MI:2364”(proximity)	0.270
SUPV3L1	BLTP3B	psi-mi:“MI:2364”(proximity)	0.270
OGFOD1	FEM1A	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (66): OGFOD1 (Affinity Capture-MS), OGFOD1 (Co-fractionation), OGFOD1 (Affinity Capture-MS), OGFOD1 (Affinity Capture-RNA), OGFOD1 (Positive Genetic), OGFOD1 (Positive Genetic), OGFOD1 (Negative Genetic), OGFOD1 (Negative Genetic), OGFOD1 (Positive Genetic), RPL10 (Negative Genetic), TAF2 (Positive Genetic), TCOF1 (Negative Genetic), TUBGCP3 (Positive Genetic), UBA2 (Positive Genetic), WDR61 (Negative Genetic)

ESM2 similar proteins: A0A1D8PNZ7, A5DMB8, A5DWN5, A5E3J7, A6ZPQ2, A7TNS4, A7TQL5, B3LQ40, C4R3K5, O01658, O13944, O60066, O74270, O94606, P14906, P20485, P32639, P32864, P38254, P38274, P40032, P40360, P43585, P50101, P53255, Q02648, Q02725, Q02959, Q02979, Q03305, Q03648, Q04311, Q06685, Q08972, Q11120, Q4WED9, Q54K96, Q54N08, Q595W7, Q5R4R3

Diamond homologs: P40032, Q01F03, Q11120, Q3U0K8, Q5R4R3, Q6DE73, Q8N543, Q9I7H9, Q3MI03

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

48 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	42
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1776 predictions. Top by Δscore:

Variant	Effect	Δscore
16:56451750:G:GT	donor_gain	1.0000
16:56453261:A:AG	acceptor_gain	1.0000
16:56453262:G:GG	acceptor_gain	1.0000
16:56453262:GAA:G	acceptor_gain	1.0000
16:56453378:G:GT	donor_gain	1.0000
16:56453381:G:GG	donor_gain	1.0000
16:56462640:G:GT	donor_gain	1.0000
16:56466147:TGCAG:T	acceptor_loss	1.0000
16:56466149:CAGAT:C	acceptor_loss	1.0000
16:56466150:A:AG	acceptor_gain	1.0000
16:56466150:AGAT:A	acceptor_gain	1.0000
16:56466151:G:GA	acceptor_gain	1.0000
16:56466151:GA:G	acceptor_gain	1.0000
16:56466151:GAT:G	acceptor_gain	1.0000
16:56466151:GATG:G	acceptor_gain	1.0000
16:56466151:GATGC:G	acceptor_gain	1.0000
16:56466241:G:GA	donor_gain	1.0000
16:56466265:GATG:G	donor_gain	1.0000
16:56466267:TGG:T	donor_loss	1.0000
16:56466269:G:GC	donor_loss	1.0000
16:56466269:G:GG	donor_gain	1.0000
16:56466270:T:A	donor_loss	1.0000
16:56466274:A:G	donor_gain	1.0000
16:56466868:T:TA	acceptor_gain	1.0000
16:56466874:A:AG	acceptor_gain	1.0000
16:56466875:G:GG	acceptor_gain	1.0000
16:56466941:G:GT	donor_gain	1.0000
16:56466973:GACT:G	donor_gain	1.0000
16:56467290:AGAT:A	donor_gain	1.0000
16:56467291:GAT:G	donor_gain	1.0000

AlphaMissense

3645 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
16:56466962:C:G	H218D	1.000
16:56466158:T:C	L152P	0.999
16:56466166:C:G	H155D	0.999
16:56466172:G:C	D157H	0.999
16:56466173:A:C	D157A	0.999
16:56466173:A:G	D157G	0.999
16:56466173:A:T	D157V	0.999
16:56466174:T:A	D157E	0.999
16:56466174:T:G	D157E	0.999
16:56466187:C:A	R162S	0.999
16:56467213:T:A	W236R	0.999
16:56467213:T:C	W236R	0.999
16:56467215:G:C	W236C	0.999
16:56467215:G:T	W236C	0.999
16:56453392:T:C	L95S	0.998
16:56466158:T:A	L152Q	0.998
16:56466168:T:A	H155Q	0.998
16:56466168:T:G	H155Q	0.998
16:56466188:G:C	R162P	0.998
16:56466197:C:A	A165D	0.998
16:56466966:A:C	Q219P	0.998
16:56467195:C:A	R230S	0.998
16:56467211:G:A	G235D	0.998
16:56453401:T:C	F98S	0.997
16:56458548:T:C	S101P	0.997
16:56462622:T:C	Y146H	0.997
16:56466163:T:C	C154R	0.997
16:56466165:C:G	C154W	0.997
16:56466167:A:C	H155P	0.997
16:56466179:T:C	L159P	0.997

dbSNP variants (sampled 300 via entrez): RS1000208322 (16:56458987 G>C), RS1000637675 (16:56466396 T>A,C), RS1000656881 (16:56459201 G>A), RS1000959883 (16:56477496 C>G,T), RS1001246685 (16:56477142 G>A), RS1001878275 (16:56460569 C>T), RS1001881783 (16:56455182 A>C,G), RS1001910439 (16:56467723 G>A,T), RS1002067288 (16:56474187 T>C), RS1002140935 (16:56474446 C>T), RS1002258282 (16:56468080 G>A), RS1002332935 (16:56460920 T>C,G), RS1002481497 (16:56453838 A>T), RS1002543978 (16:56464384 A>G), RS1002987236 (16:56450642 C>G)

Disease associations

OMIM: gene MIM:615857 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4523398 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 533 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL3646221	VADADUSTAT	4	533

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

3 potent at pChembl≥5 of 3 total, top 3 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
5.85	IC50	1400	nM	VADADUSTAT
5.68	IC50	2100	nM	CHEMBL4163812
5.29	IC50	5100	nM	CHEMBL3646117

PubChem BioAssay actives

5 with measured affinity, of 5 total; 5 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
2-[(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carbonyl)amino]acetic acid	1543455: Inhibition of recombinant human OGFOD1 using 2OG as substrate and Fe2 as co-factor assessed as hydroxylation incubated for 15 mins in presence of L-ascorbate by MALDI-TOF MS analysis	ic50	1.0000	uM
Molidustat	1543455: Inhibition of recombinant human OGFOD1 using 2OG as substrate and Fe2 as co-factor assessed as hydroxylation incubated for 15 mins in presence of L-ascorbate by MALDI-TOF MS analysis	ic50	1.0000	uM
Vadadustat	1543455: Inhibition of recombinant human OGFOD1 using 2OG as substrate and Fe2 as co-factor assessed as hydroxylation incubated for 15 mins in presence of L-ascorbate by MALDI-TOF MS analysis	ic50	1.4000	uM
2-[(1,3-dicyclohexyl-4-hydroxy-2,6-dioxopyrimidine-5-carbonyl)amino]acetic acid	1543455: Inhibition of recombinant human OGFOD1 using 2OG as substrate and Fe2 as co-factor assessed as hydroxylation incubated for 15 mins in presence of L-ascorbate by MALDI-TOF MS analysis	ic50	2.1000	uM
tert-butyl 6-[3-oxo-4-(triazol-1-yl)-1H-pyrazol-2-yl]pyridine-3-carboxylate	1543455: Inhibition of recombinant human OGFOD1 using 2OG as substrate and Fe2 as co-factor assessed as hydroxylation incubated for 15 mins in presence of L-ascorbate by MALDI-TOF MS analysis	ic50	5.1000	uM

CTD chemical–gene interactions

37 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression, affects expression, decreases methylation	5
entinostat	decreases expression, affects cotreatment	2
Estradiol	affects cotreatment, increases expression	2
aristolochic acid I	increases expression	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
trichostatin A	decreases expression	1
afimoxifene	decreases reaction, increases expression	1
di-n-butylphosphoric acid	affects expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
jinfukang	decreases expression	1
Resveratrol	affects cotreatment, increases expression	1
Arsenic Trioxide	affects cotreatment, decreases expression	1
Air Pollutants	decreases expression, increases abundance	1
Ascorbic Acid	affects cotreatment, decreases expression	1
Cadmium	increases expression	1
Cisplatin	decreases expression	1
Coal	decreases expression, increases abundance	1
Coumestrol	increases expression	1
Doxorubicin	decreases expression	1
Estrogens	decreases reaction, increases expression	1
Lead	decreases expression	1
Methotrexate	increases expression	1
Methyl Methanesulfonate	increases expression	1
Nickel	decreases expression	1
Phenobarbital	affects expression	1
Plant Extracts	affects cotreatment, increases expression	1
Progesterone	increases expression, affects cotreatment	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4340711	Binding	Inhibition of recombinant human OGFOD1 using 2OG as substrate and Fe2 as co-factor assessed as hydroxylation incubated for 15 mins in presence of L-ascorbate by MALDI-TOF MS analysis	Inhibition of a viral prolyl hydroxylase. — Bioorg Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.